Role of erythropoietin and its receptor in the development of endometriosis in rats

Basit Öğe Kaydı
dc.contributor.authorGünal, Mehmet Yalçın
dc.contributor.authorOzansoy, Mehmet
dc.contributor.authorKılıç, Ülkan
dc.contributor.authorKeskin, İlknur
dc.contributor.authorÖzdemir, Ekrem Musa
dc.contributor.authorAslan, İsmail
dc.contributor.authorKılıç, Ertuğrul
dc.date.accessioned2021-02-19T21:29:05Z
dc.date.available2021-02-19T21:29:05Z
dc.date.issued2019
dc.departmentALKÜ
dc.description.abstractObjective: Besides its hematopoietic function, erythropoietin (EPO) may protect tissues from degenerative disorders. As such, EPO and its receptors were revealed in nonhematopoietic cells, including stromal and endometrial epithelial cells. However, the role of EPO in endometrial disorders is still unknown. Here, we aimed to examine the role of EPO and its receptor activation in the development of endometriosis in rats. Material and Methods: Animals were treated with EPO, darbepoietin (the synthetic form of EPO) or EPO’s receptor activator, methoxy polyethylene glycol-epoetin beta (MIRCERA), after development of endometriosis. Endometriosis was induced by estrogen-administration following surgical attachment of endometrial surface on the inner abdominal wall. Treatments were started 3 weeks after induction of endometriosis and continued for the following 3 weeks. For the analysis of recurrence of endometriosis, additional analyses were conducted 3 weeks after cessation of treatments. Results: As compared with vehicle-treated animals, lesion size was reduced significantly and recurrence of endometriosis was not observed in all treatment groups. Histopathologic examination revealed that EPO and darbepoietin were more effective than MIRCERA- and vehicle-treated animals. Conclusion: Here we provide evidence that EPO is a promising candidate for the treatment of endometriosis. Our histopathologic results in particular indicate that EPO is more effective than its receptor activator MIRCERA in the development endometriosis. (J Turk Ger Gynecol Assoc 2019; 20: 41-6)
dc.identifier.doi10.4274/jtgga.galenos.2018.2018.0039
dc.identifier.endpage46en_US
dc.identifier.issn1309-0399
dc.identifier.issn1309-0380
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ3
dc.identifier.startpage41en_US
dc.identifier.urihttps://doi.org/10.4274/jtgga.galenos.2018.2018.0039
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TXpZd05qSTRPQT09
dc.identifier.urihttps://hdl.handle.net/20.500.12868/963
dc.identifier.volume20en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthor0-belirlenecek
dc.language.isoen
dc.relation.ispartofJournal of the Turkish-German Gynecological Association
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleRole of erythropoietin and its receptor in the development of endometriosis in rats
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu